AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug
BioSpace
New mid-stage data from Biogen's Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer's disease and raise questions that could soon be elucidated by anti-tau cand
pharminent
July 15, 2026 (Last updated: July 20, 2026)
BioSpace
New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s disease and raise questions that could soon be elucidated by anti-tau cand
